Deutsche Bank AG Has $11.70 Million Position in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Deutsche Bank AG boosted its position in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 54.6% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 145,242 shares of the company's stock after acquiring an additional 51,289 shares during the period. Deutsche Bank AG owned about 0.28% of PROCEPT BioRobotics worth $11,695,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. FMR LLC increased its position in PROCEPT BioRobotics by 11.9% during the 4th quarter. FMR LLC now owns 8,159,208 shares of the company's stock worth $656,979,000 after purchasing an additional 866,328 shares in the last quarter. Perpetual Ltd acquired a new position in PROCEPT BioRobotics during the 4th quarter worth $66,972,000. Wellington Management Group LLP increased its position in shares of PROCEPT BioRobotics by 38.8% in the 4th quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company's stock worth $120,051,000 after purchasing an additional 416,819 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of PROCEPT BioRobotics by 6.1% in the 4th quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company's stock valued at $413,907,000 after purchasing an additional 297,075 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of PROCEPT BioRobotics during the fourth quarter worth about $22,422,000. Hedge funds and other institutional investors own 89.46% of the company's stock.

Insiders Place Their Bets

In other news, CFO Kevin Waters sold 733 shares of PROCEPT BioRobotics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $41,824.98. Following the completion of the transaction, the chief financial officer now directly owns 107,991 shares in the company, valued at approximately $6,161,966.46. The trade was a 0.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Reza Zadno sold 5,475 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $312,403.50. Following the sale, the chief executive officer now owns 173,070 shares of the company's stock, valued at approximately $9,875,374.20. This represents a 3.07% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,455 shares of company stock valued at $368,322 in the last three months. 17.40% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have issued reports on PRCT shares. Bank of America cut their target price on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating on the stock in a report on Friday, April 25th. Morgan Stanley decreased their target price on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Finally, Truist Financial lowered their price target on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, April 11th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, PROCEPT BioRobotics has an average rating of "Moderate Buy" and a consensus target price of $90.00.

PROCEPT BioRobotics Stock Performance

Shares of NASDAQ PRCT traded down $0.55 during mid-day trading on Wednesday, hitting $58.64. The company had a trading volume of 84,710 shares, compared to its average volume of 814,302. The business's 50-day simple moving average is $55.32 and its 200-day simple moving average is $71.46. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. PROCEPT BioRobotics Co. has a 12 month low of $47.04 and a 12 month high of $103.81. The firm has a market cap of $3.24 billion, a P/E ratio of -30.07 and a beta of 1.10.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.04. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The firm had revenue of $69.16 million during the quarter, compared to the consensus estimate of $65.39 million. During the same quarter in the previous year, the company posted ($0.51) EPS. The business's revenue for the quarter was up 55.5% compared to the same quarter last year. As a group, analysts predict that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).